Ofatumumab (Arzerra) approved for recurrent or progressive chronic lymphocytic leukemia (CLL)

Last Updated on

January 20, 2016 – The American Food and Drug Administration (FDA) just approved Ofatumumab (Arzerra)  Injection for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL). Ofatumumab, also known as HuMax-CD20, is a fully human monoclonal antibody directed against the CD20 protein which appears to inhibit early-stage B lymphocyte activation. Ofatumumab IOfatumumab (Arzerra) was previously approved for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy was considered inappropriate and also for patients with CLL refractory to Fludarabine and Alemtuzumab (Campath).

The recommended dose and schedule for Ofatumumab (Arzerra) therapy in this indication is 300 mg by intravenous infusion on day 1 followed by 1,000 mg on day 8 and then 7 weeks later and every 8 weeks thereafter for up to a maximum of 2 years.

This new approval was based on demonstration of an improvement in progression-free survival (PFS) in a randomized, open-label trial comparing Ofatumumab (Arzerra) to observation in patients whose disease had a complete or partial response after at least two lines of prior therapy. A total of 474 patients were randomized (1:1) to Ofatumumab (Arzerra) (n=238) or observation (n=236). The median age was 64.5 years (range 33-87).  Patients in the Ofatumumab (Arzerra) arm had received a median of 2 prior therapies (range 2-5).  The investigator-assessed median PFS was 29.4 months (95% CI: 26.2, 34.2) and 15.2 months (95% CI: 11.8, 18.8) in the Ofatumumab (Arzerra) and observation arms, respectively [HR: 0.50 (95% CI: 0.38, 0.66), p-value < 0.0001].

Ofatumumab (Arzerra) comes with serious adverse effects for some patients. The most common adverse reactions (greater than or equal to 10%) in patients treated with Ofatumumab (Arzerra) therapy were infusion reactions, neutropenia and upper respiratory tract infection. Thirty-three percent of patients treated with Ofatumumab (Arzerra) reported serious adverse reactions. The most common serious adverse reactions were pneumonia, pyrexia and neutropenia (including febrile neutropenia). In addition, Ofatumumab (Arzerra) comes with a Boxed Warning which very prominently warns about the possibility of Hepatitis B Virus (HBV) Reactivation in patients receiving CD20-directed cytolytic antibodies, including Ofatumumab (Arzerra), resulting in some cases  in fulminant hepatitis, hepatic failure, and death. Progressive Multifocal Leukoencephalopathy (PML) resulting in death can occur in patients receiving CD20-directed cytolytic antibodies, including Ofatumumab (Arzerra), as well.

Tags: , , , , , , , , ,
About the Author
thassodotcom Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Leave a Reply

Optional: Social Subscribe/Login




avatar
  Subscribe  
Notify of

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Scientists use gene-editing tool CRISPR in attempt to cure HIV September 13, 2019
    The first attempt to use the gene-editing tool CRISPR to cure HIV infection was unsuccessful but the approach does show promise.
  • New cardiac fibrosis study identifies key proteins that translate into heart disease September 12, 2019
    Using cutting-edge technologies, researchers at Duke-NUS Medical School, Singapore, have developed the first genome-wide dataset on protein translation during fibroblast activation, revealing a network of RNA-binding proteins (RBPs) that play a key role in the formation of disease-causing fibrous tissue in the heart. Their findings, published in the journal Circulation, could help in the search […]
  • How your genes affect the number on your scale September 12, 2019
    Could your genes be keeping you from losing weight?
  • Scientists identify gene as master regulator in schizophrenia September 11, 2019
    Using computational tools to investigate gene transcription networks in large collections of brain tissues, a scientific team has identified a gene that acts as a master regulator of schizophrenia during early human brain development. The findings may lay the groundwork for future treatments for the highly complex neuropsychiatric disorder.
  • How your DNA takes shape makes a big difference in your health September 11, 2019
    The more we learn about our genome, the more mysteries arise. For example, how can people with the same disease-causing mutation have different disease progression and symptoms? And despite the fact that it's been more than 15 years since the human genome was sequenced, why can't we explain the significance of the vast majority of […]
Top